Correction to “‘Clinical practice guideline on bladder cancer (Part I)’, ‘Clinical practice guideline on bladder cancer (Part II)’ and ‘Clinical practice guideline on bladder cancer (Part III)’”
Correction to “‘Clinical practice guideline on bladder cancer (Part I)’, ‘Clinical practice guideline on bladder cancer (Part II)’ and ‘Clinical practice guideline on bladder cancer (Part III)’”. // UroPrecision. – 2025. – DOI: 10.1002/uro2.70055. – URL: https://onlinelibrary.wiley.com/doi/10.1002/uro2.70055?af=R
(2025). Correction to “‘Clinical practice guideline on bladder cancer (Part I)’, ‘Clinical practice guideline on bladder cancer (Part II)’ and ‘Clinical practice guideline on bladder cancer (Part III)’”. UroPrecision. https://doi.org/10.1002/uro2.70055
“Correction to “‘Clinical practice guideline on bladder cancer (Part I)’, ‘Clinical practice guideline on bladder cancer (Part II)’ and ‘Clinical practice guideline on bladder cancer (Part III)’”.” UroPrecision, 2025. doi:10.1002/uro2.70055.
@article{article110008,
title = {Correction to “‘Clinical practice guideline on bladder cancer (Part I)’, ‘Clinical practice guideline on bladder cancer (Part II)’ and ‘Clinical practice guideline on bladder cancer (Part III)’”},
journal = {UroPrecision},
year = {2025},
doi = {10.1002/uro2.70055},
url = {https://onlinelibrary.wiley.com/doi/10.1002/uro2.70055?af=R}
}
Objective To assess prostate‐specific antigen (PSA) testing according to income, age, and region of residence in Sweden. Patients and Methods We conducted a nationwide, population‐based open cohort study of men aged 40–90 years in...